Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 2nd Quarter - Report

FABRE-KRAMER PHARMACEUTICALS, INC

via COVINGTON & BURLING LLP

2nd Quarter (Apr 1 - June 30) · 2016Posted Jul 15, 2016Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: FABRE-KRAMER PHARMACEUTICALS, INC
Description: Pharmaceutical company
Location: Texas · United States of America

Registrant

Firm: COVINGTON & BURLING LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
Policy regarding demonstration of effectiveness for new drug approvals.
LobbyistsGARY HEIMBERG
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

FABRE-KRAMER PHARMACEUTICALS, INC — Receipts Report